Official Title
Named Patient Use Program to Provide Abemaciclib for the Treatment of Metastatic Breast Cancer
Brief Summary

The treating physician/investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the expanded access program.

Status
Available
EA Type
Individual Patients
Conditions
Metastatic Breast Cancer
Interventions

Drug: Abemaciclib
Administered orally.
Other Name: LY2835219

Eligibility Criteria

Inclusion Criteria: - Patients with hormone receptor positive metastatic breast cancer for whom there is reasonable expectation that abemaciclib may provide clinical benefit and who are suitable to receive abemaciclib.

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years
Countries
Australia
Canada
Egypt
India
Italy
Korea, Republic of
Malaysia
Singapore
South Africa
Spain
Switzerland
Taiwan
Thailand
United Kingdom
Contacts

There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or
1-317-615-4559
clinicaltrials.gov@lilly.com

Sponsors / Collaborators
Eli Lilly and Company
NCT Number
NCT03763604
MeSH Terms
Breast Neoplasms